Taurocholic acid

DB04348

small molecule approved experimental

Deskripsi

The product of conjugation of cholic acid with taurine. Its sodium salt is the chief ingredient of the bile of carnivorous animals. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic.

Struktur Molekul 2D

Berat 515.703
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

556 Data
Lepirudin The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Taurocholic acid.
Bivalirudin The risk or severity of bleeding and bruising can be increased when Bivalirudin is combined with Taurocholic acid.
Alteplase The risk or severity of bleeding and bruising can be increased when Alteplase is combined with Taurocholic acid.
Urokinase The risk or severity of bleeding and bruising can be increased when Urokinase is combined with Taurocholic acid.
Reteplase The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Taurocholic acid.
Anistreplase The risk or severity of bleeding and bruising can be increased when Anistreplase is combined with Taurocholic acid.
Tenecteplase The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Taurocholic acid.
Drotrecogin alfa The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Taurocholic acid.
Streptokinase The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Taurocholic acid.
Dicoumarol The risk or severity of bleeding and bruising can be increased when Dicoumarol is combined with Taurocholic acid.
Argatroban The risk or severity of bleeding and bruising can be increased when Argatroban is combined with Taurocholic acid.
Ardeparin The risk or severity of bleeding and bruising can be increased when Ardeparin is combined with Taurocholic acid.
Phenindione The risk or severity of bleeding and bruising can be increased when Phenindione is combined with Taurocholic acid.
Fondaparinux The risk or severity of bleeding and bruising can be increased when Fondaparinux is combined with Taurocholic acid.
Warfarin The risk or severity of bleeding and bruising can be increased when Warfarin is combined with Taurocholic acid.
Pentosan polysulfate The risk or severity of bleeding and bruising can be increased when Pentosan polysulfate is combined with Taurocholic acid.
Phenprocoumon The risk or severity of bleeding and bruising can be increased when Phenprocoumon is combined with Taurocholic acid.
Heparin The risk or severity of bleeding and bruising can be increased when Heparin is combined with Taurocholic acid.
Enoxaparin The risk or severity of bleeding and bruising can be increased when Enoxaparin is combined with Taurocholic acid.
Acenocoumarol The risk or severity of bleeding and bruising can be increased when Acenocoumarol is combined with Taurocholic acid.
4-hydroxycoumarin The risk or severity of bleeding and bruising can be increased when 4-hydroxycoumarin is combined with Taurocholic acid.
Coumarin The risk or severity of bleeding and bruising can be increased when Coumarin is combined with Taurocholic acid.
Ximelagatran The risk or severity of bleeding and bruising can be increased when Ximelagatran is combined with Taurocholic acid.
Desmoteplase The risk or severity of bleeding and bruising can be increased when Desmoteplase is combined with Taurocholic acid.
Ancrod The risk or severity of bleeding and bruising can be increased when Ancrod is combined with Taurocholic acid.
Rivaroxaban The risk or severity of bleeding and bruising can be increased when Rivaroxaban is combined with Taurocholic acid.
Sulodexide The risk or severity of bleeding and bruising can be increased when Sulodexide is combined with Taurocholic acid.
Semuloparin The risk or severity of bleeding and bruising can be increased when Semuloparin is combined with Taurocholic acid.
Idraparinux The risk or severity of bleeding and bruising can be increased when Idraparinux is combined with Taurocholic acid.
Astaxanthin The risk or severity of bleeding and bruising can be increased when Astaxanthin is combined with Taurocholic acid.
Apixaban The risk or severity of bleeding and bruising can be increased when Apixaban is combined with Taurocholic acid.
Otamixaban The risk or severity of bleeding and bruising can be increased when Otamixaban is combined with Taurocholic acid.
Amediplase The risk or severity of bleeding and bruising can be increased when Amediplase is combined with Taurocholic acid.
Danaparoid The risk or severity of bleeding and bruising can be increased when Danaparoid is combined with Taurocholic acid.
Dalteparin The risk or severity of bleeding and bruising can be increased when Dalteparin is combined with Taurocholic acid.
Tinzaparin The risk or severity of bleeding and bruising can be increased when Tinzaparin is combined with Taurocholic acid.
(R)-warfarin The risk or severity of bleeding and bruising can be increased when (R)-warfarin is combined with Taurocholic acid.
Ethyl biscoumacetate The risk or severity of bleeding and bruising can be increased when Ethyl biscoumacetate is combined with Taurocholic acid.
Nadroparin The risk or severity of bleeding and bruising can be increased when Nadroparin is combined with Taurocholic acid.
Ditazole The risk or severity of bleeding and bruising can be increased when Ditazole is combined with Taurocholic acid.
Sodium citrate The risk or severity of bleeding and bruising can be increased when Sodium citrate is combined with Taurocholic acid.
Dextran The risk or severity of bleeding and bruising can be increased when Dextran is combined with Taurocholic acid.
Bemiparin The risk or severity of bleeding and bruising can be increased when Bemiparin is combined with Taurocholic acid.
Parnaparin The risk or severity of bleeding and bruising can be increased when Parnaparin is combined with Taurocholic acid.
Desirudin The risk or severity of bleeding and bruising can be increased when Desirudin is combined with Taurocholic acid.
Antithrombin Alfa The risk or severity of bleeding and bruising can be increased when Antithrombin Alfa is combined with Taurocholic acid.
Protein C The risk or severity of bleeding and bruising can be increased when Protein C is combined with Taurocholic acid.
Antithrombin III human The risk or severity of bleeding and bruising can be increased when Antithrombin III human is combined with Taurocholic acid.
Letaxaban The risk or severity of bleeding and bruising can be increased when Letaxaban is combined with Taurocholic acid.
Darexaban The risk or severity of bleeding and bruising can be increased when Darexaban is combined with Taurocholic acid.
Nafamostat The risk or severity of bleeding and bruising can be increased when Nafamostat is combined with Taurocholic acid.
Monteplase The risk or severity of bleeding and bruising can be increased when Monteplase is combined with Taurocholic acid.
Gabexate The risk or severity of bleeding and bruising can be increased when Gabexate is combined with Taurocholic acid.
Fluindione The risk or severity of bleeding and bruising can be increased when Fluindione is combined with Taurocholic acid.
Protein S human The risk or severity of bleeding and bruising can be increased when Protein S human is combined with Taurocholic acid.
Brinase The risk or severity of bleeding and bruising can be increased when Brinase is combined with Taurocholic acid.
Clorindione The risk or severity of bleeding and bruising can be increased when Clorindione is combined with Taurocholic acid.
Diphenadione The risk or severity of bleeding and bruising can be increased when Diphenadione is combined with Taurocholic acid.
Tioclomarol The risk or severity of bleeding and bruising can be increased when Tioclomarol is combined with Taurocholic acid.
Melagatran The risk or severity of bleeding and bruising can be increased when Melagatran is combined with Taurocholic acid.
Saruplase The risk or severity of bleeding and bruising can be increased when Saruplase is combined with Taurocholic acid.
(S)-Warfarin The risk or severity of bleeding and bruising can be increased when (S)-Warfarin is combined with Taurocholic acid.
Tocopherylquinone The risk or severity of bleeding and bruising can be increased when Tocopherylquinone is combined with Taurocholic acid.
Dabigatran The risk or severity of bleeding and bruising can be increased when Dabigatran is combined with Taurocholic acid.
Dabigatran etexilate The risk or severity of bleeding and bruising can be increased when Dabigatran etexilate is combined with Taurocholic acid.
Edoxaban The risk or severity of bleeding and bruising can be increased when Edoxaban is combined with Taurocholic acid.
Betrixaban The risk or severity of bleeding and bruising can be increased when Betrixaban is combined with Taurocholic acid.
Troxerutin The risk or severity of bleeding and bruising can be increased when Troxerutin is combined with Taurocholic acid.
Edetic acid The risk or severity of bleeding and bruising can be increased when Edetic acid is combined with Taurocholic acid.
Reviparin The risk or severity of bleeding and bruising can be increased when Reviparin is combined with Taurocholic acid.
Dermatan sulfate The risk or severity of bleeding and bruising can be increased when Dermatan sulfate is combined with Taurocholic acid.
SR-123781A The risk or severity of bleeding and bruising can be increased when SR-123781A is combined with Taurocholic acid.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Taurocholic acid.
Eptifibatide The risk or severity of adverse effects can be increased when Eptifibatide is combined with Taurocholic acid.
Ticlopidine The risk or severity of adverse effects can be increased when Ticlopidine is combined with Taurocholic acid.
Anagrelide The risk or severity of adverse effects can be increased when Anagrelide is combined with Taurocholic acid.
Clopidogrel The risk or severity of adverse effects can be increased when Clopidogrel is combined with Taurocholic acid.
Tirofiban The risk or severity of adverse effects can be increased when Tirofiban is combined with Taurocholic acid.
Pentoxifylline The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Taurocholic acid.
Acetylsalicylic acid The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Taurocholic acid.
Dipyridamole The risk or severity of adverse effects can be increased when Dipyridamole is combined with Taurocholic acid.
Sulfinpyrazone The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Taurocholic acid.
Cilostazol The risk or severity of adverse effects can be increased when Cilostazol is combined with Taurocholic acid.
Ridogrel The risk or severity of adverse effects can be increased when Ridogrel is combined with Taurocholic acid.
Epoprostenol The risk or severity of adverse effects can be increased when Epoprostenol is combined with Taurocholic acid.
Resveratrol The risk or severity of adverse effects can be increased when Resveratrol is combined with Taurocholic acid.
Nimesulide The risk or severity of adverse effects can be increased when Nimesulide is combined with Taurocholic acid.
Tesmilifene The risk or severity of adverse effects can be increased when Tesmilifene is combined with Taurocholic acid.
Defibrotide The risk or severity of adverse effects can be increased when Defibrotide is combined with Taurocholic acid.
Beraprost The risk or severity of adverse effects can be increased when Beraprost is combined with Taurocholic acid.
Ibudilast The risk or severity of adverse effects can be increased when Ibudilast is combined with Taurocholic acid.
Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with Taurocholic acid.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Taurocholic acid.
Prasugrel The risk or severity of adverse effects can be increased when Prasugrel is combined with Taurocholic acid.
Cangrelor The risk or severity of adverse effects can be increased when Cangrelor is combined with Taurocholic acid.
Tranilast The risk or severity of adverse effects can be increased when Tranilast is combined with Taurocholic acid.
Triflusal The risk or severity of adverse effects can be increased when Triflusal is combined with Taurocholic acid.
Ticagrelor The risk or severity of adverse effects can be increased when Ticagrelor is combined with Taurocholic acid.
Icosapent ethyl The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Taurocholic acid.
Vorapaxar The risk or severity of adverse effects can be increased when Vorapaxar is combined with Taurocholic acid.

Target Protein

Ileal sodium/bile acid cotransporter SLC10A2
G-protein coupled bile acid receptor 1 GPBAR1
Bile salt-activated lipase CEL
Bile acid receptor NR1H4
Gastrotropin FABP6

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 17 • International brands: 0
Produk
  • Acidobyl
    Tablet • - • Oral • Canada • OTC • Approved
  • Aid-lax Tab
    Tablet • - • Oral • Canada • OTC • Approved
  • Alsiline
    Tablet • - • Oral • Canada • OTC • Approved
  • Bicholate Lilas
    Tablet • - • Oral • Canada • OTC • Approved
  • Bicholate Lilas Tab
    Tablet • - • Oral • Canada • OTC • Approved
  • Bilex Tab
    Tablet • - • Oral • Canada • OTC • Approved
  • Duchol Ect
    Tablet, delayed release • - • Oral • Canada • OTC • Approved
  • Herbalax Forte No 70 Tab
    Tablet • - • Oral • Canada • OTC • Approved
Menampilkan 8 dari 17 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul